Recent updates on access to hepatitis C medications in Canada
In February 2017, the pan-Canadian Pharmaceutical Alliance (pCPA), the body that represents provinces and territories in negotiations with pharmaceutical companies, reached a deal with several companies for lower prices for six hepatitis C medications.
After the pCPA negotiates a deal, each province or territory decides how to implement changes to its formulary.
The following provincial governments have announced changes to their formularies:
Alberta expands drug coverage for hepatitis C patients (Global News)
Quebec has added Epclusa, Zepatier and daclatasvir to its formulary
Nova Scotia expands drug coverage for hepatitis C (Pharmacare news)
For more information on hepatitis C treatment coverage, see Treatment coverage in your region.